ライフサイエンスコーパス: all-cause mortality

1 and predictor of a range of morbidities and all-cause mortality.

2 No impregnations significantly reduced all-cause mortality.

3 The primary outcome was all-cause mortality.

4 f CVD and of other major causes of death and all-cause mortality.

5 nflammasome gene modules was associated with all-cause mortality.

6 ociated with either higher or lower rates of all-cause mortality.

7 lung disease, liver disease, and cancer) and all-cause mortality.

8 ating physiologic impairment, and predicting all-cause mortality.

9 oods) was independently related with risk of all-cause mortality.

10 were both associated with a higher risk for all-cause mortality.

11 The primary outcome measure was all-cause mortality.

12 ion between these 12 food groups and risk of all-cause mortality.

13 but not with CV-related hospitalizations or all-cause mortality.

14 raphe was not significantly associated with all-cause mortality.

15 to examine associations of plasma TMAO with all-cause mortality.

16 71 (95% confidence interval: 0.66, 0.76) for all-cause mortality.

17 ach cause of death to overall disparities in all-cause mortality.

18 4) for the number of missing teeth regarding all-cause mortality.

19 Age was the most important predictor for all-cause mortality.

20 risk for recurrent MI and CHD events but not all-cause mortality.

21 ailable on flavonoid classes and lignans and all-cause mortality.

22 ween vegetables, fruits, nuts, and dairy and all-cause mortality.

23 not independently associated with increased all-cause mortality.

24 was a consistent association between AHI and all-cause mortality.

25 ted with increased cardiovascular events and all-cause mortality.

26 as potential mechanisms linking knee SxOA to all-cause mortality.

27 events, and 0.96 (95% CI: 0.87 to 1.06) for all-cause mortality.

28 0.688 for ADA HbA1c clinical categories for all-cause mortality.

29 ine the relation of knee SxOA to the risk of all-cause mortality.

30 d the association of total water intake with all-cause mortality.

31 PEEP compared with low PEEP increased 28-day all-cause mortality.

32 The primary endpoint was 30-day all-cause mortality.

33 the association between 25(OH)D and rate of all-cause mortality.

34 ovascular causes; the secondary endpoint was all-cause mortality.

35 the components of the composite outcome and all-cause mortality.

36 sored graft loss, and secondary endpoint was all-cause mortality.

37 CI 0.31-0.87; p=0.0107]; treatment-emergent all-cause mortality 0.45 [0.24-0.83; 0.0094]; idiopathic

38 0.007), and a 12% relative risk reduction in all-cause mortality (0.88, 0.81-0.95; p=0.002), with low

39 d hazard ratio [95% confidence interval] for all-cause mortality=1.42 (1.14-1.77); P=0.002), whereas

40 he end of 2012, 5302 (6%) patients had died (all-cause mortality 118 per 10 000 person-years, 95% CI

41 Both all-cause mortality (14% vs 19%, P = .39) and EVD-specif

42 nificant difference between groups in 30-day all-cause mortality (16.7% with AC607; 11.8% with placeb

43 The annual incidence of all-cause mortality (19.00 vs. 42.89 events per 1000 per

44 with zero were 2.92 (95%CI: 2.53, 3.38) for all-cause mortality, 3.15 (95%CI: 2.44, 4.05) for CVD mo

45 Secondary outcomes included 30-day all-cause mortality, 30-day readmission, hospital length

46 bsolute BNP thresholds reduced postdischarge all-cause mortality (7 of 8 studies) and the composite o

47 ears, respectively), and a 15% lower rate of all-cause mortality (79.9 vs. 94.2 per 1,000 person-year

48 ean 3.22% (95% CI: 2.80%, 3.64%) increase in all-cause mortality, a 0.54% (95% CI: -0.17%, 1.25%) inc

49 scular events, cardiovascular mortality, and all-cause mortality according to on-treatment concentrat

50 lculated an adjusted daily hazard rate using all-cause mortality, accounting for patient comorbiditie

51 resolution estimates of under-5 and neonatal all-cause mortality across 46 countries in Africa.

52 ficant nonlinear association between BMI and all-cause mortality across the range of BMI was seen, pe

53 All-cause mortality, acute myocardial infarction (AMI),

54 nsumption was associated with lower risks of all-cause mortality (adjusted HR = 0.83 [95% CI 0.74-0.9

55 etabolic diseases, psychiatric disorders and all-cause mortality, affect 25-30% of adults worldwide.

56 d from 74% to 95% and was protective against all-cause mortality after accounting for demographics, c

57 utcome and Measures: Our primary outcome was all-cause mortality after adjusting for clinically relev

58 idence that CD4:CD8 ratio was prognostic for all-cause mortality after adjustment for other factors:

59 eloping diabetes mellitus and its effects on all-cause mortality after radiopeptide therapy for neuro

60 .65; 95% confidence interval, 0.50-0.84) and all-cause mortality alone (hazard ratio, 0.62; 95% confi

61 Overall, all-cause mortality also was lower with paroxysmal (3.0%

62 CAC with risk of cardiovascular disease and all-cause mortality among dialysis-naive patients with C

63 a male donor, was associated with increased all-cause mortality among male recipients but not among

64 prevention ICDs are efficacious at reducing all-cause mortality among patients with nonischemic card

65 prevention ICDs were hypothesized to reduce all-cause mortality among patients with nonischemic card

66 ed with reduced cancer-specific mortality or all-cause mortality among patients with prostate cancer

67 Nonprogrammed VA with a catheter predicted all-cause mortality among patients with transplant failu

68 the association between body mass index and all-cause mortality among people with type 2 diabetes.

69 The primary outcome was all-cause mortality, analyzed with Cox proportional haza

70 terval [CI]: 0.55 to 0.90) decreased risk of all-cause mortality and 67% (HR: 0.33; 95% CI: 0.19 to 0

71 Hazard ratios (HRs) of all-cause mortality and 95% confidence intervals (CIs) w

72 cteristics, and Charlson comorbidity scores, all-cause mortality and cancer-specific mortality were s

73 bic splines, we plotted the hazard ratio for all-cause mortality and cardiovascular events against th

74 the first decade after donation, the risk of all-cause mortality and cardiovascular events is no high

75 hisms ([SNPs] rs10455872 and rs3798220) with all-cause mortality and cardiovascular mortality by Cox

76 Outcomes of interest were all-cause mortality and disability 1 year after the proc

77 The main outcomes were all-cause mortality and drug discontinuation.

78 Hazard ratios for all-cause mortality and heart failure and absolute risks

79 adjusted associations between heart rate and all-cause mortality and heart failure hospitalization us

80 Functional class and the composite outcome (all-cause mortality and HF hospitalization).

81 ficantly improve the combined event rate for all-cause mortality and HF readmissions (hazard ratio, 0

82 e primary end point was dual: a composite of all-cause mortality and HF readmissions in 180 days and

83 The primary endpoint was the composite of all-cause mortality and HF rehospitalization.

84 f SGLT2i was associated with a lower rate of all-cause mortality and hospitalization for heart failur

85 There was an association between reduced all-cause mortality and ICD in patients </=70 years of a

86 prediction equations for CKD progression and all-cause mortality and investigated non-GFR determinant

87 The secondary outcome was all-cause mortality and length of stay in the intensive

88 The primary outcomes were 30-days all-cause mortality and long-term survival at end of the

89 DM is associated with increased rates of all-cause mortality and major adverse events despite fav

90 Associations between all-cause mortality and reported intakes of nonfermented

91 This study evaluated rates of all-cause mortality and self-harm in association with cl

92 The association of all-cause mortality and SOTR with PTM did not vary by tr

93 The association between nitrate use and all-cause mortality and the composite of all-cause morta

94 The primary endpoints were all-cause mortality and the composite of mortality or un

95 Our primary outcomes were all-cause mortality and the Glasgow Outcome Scale.

96 eding and thereby have a favorable impact on all-cause mortality and the need for rehospitalization.

97 oke, myocardial infarction, or death, 30-day all-cause mortality, and 1-year stroke.

98 Lung cancer-specific mortality, all-cause mortality, and 30-, 60-, and 90-day treatment

99 e explored the relationship between TMAO and all-cause mortality, and determined whether this associa

100 n analyzed time to event (cardiac mortality, all-cause mortality, and HF-related readmission) startin

101 exist, but whether these are surrogates for all-cause mortality, and how their performance compares,

102 Baseline characteristics, 30-day to 1-year all-cause mortality, and repeat hospitalization were com

103 with fibrosis were at an increased risk for all-cause mortality, and this risk increased with increa

104 currence of superficial vein-thrombosis, and all-cause mortality, and was not associated with more ma

105 ceiving OADs was performed to analyze 30-day all-cause mortality as main outcome.

106 cific risk scores with other tools that have all-cause mortality as the outcome.

107 grafting was associated with a reduction in all-cause mortality at 12 years of follow-up (HR, 0.79 [

108 Cumulative incidence of all-cause mortality at 2 years in patients with and with

109 (P < .001) AUROC for all-cause mortality at 3 and 5 years was 0.65-0.68.

110 djusted hazard ratio for acute rejection and all-cause mortality at 3 years in recipients who have ex

111 rventions (6% versus 17%; P=0.004) and lower all-cause mortality at 30 days (1% versus 14%; P<0.001)

112 f ICU and hospital stay, adverse events, and all-cause mortality at 30 days after surgery.

113 The primary endpoint was all-cause mortality at 30 days.

114 currence of superficial vein-thrombosis, and all-cause mortality at 45 days in the per-protocol popul

115 silateral amputation, binary restenosis, and all-cause mortality at 6 and 24 months.

116 alth Stroke Scale (NIHSS) score at 24 hours, all-cause mortality at 90 days, and procedure-related se

117 The primary outcome was all-cause mortality at any timepoint.

118 Secondary outcomes included all-cause mortality at week 24, the time to clinical res

119 with the pooled analysis, meta-analyses for all-cause mortality at week 52 also showed a clinically

120 MELD <8; FIB-4 <3 for HD and HCC, and <2 for all-cause mortality, below which <1.5% developed HD and

121 ut this was outweighed by cardiovascular and all-cause mortality benefits.

122 We compared 30 day all-cause mortality between patients receiving appropria

123 cluding surgery), there was no difference in all-cause mortality between Vmax 4 to 4.49 m/s and Vmax

124 evious evidence suggesting that LTL predicts all-cause mortality beyond its association with age.

125 ssociated with recurrent cancer mortality or all-cause mortality (both P > 0.45).

126 ndependently associated with a lower risk of all-cause mortality, but not readmission.

127 n attendance at religious services and lower all-cause mortality, but the literature on associations

128 ry haematological malignancies and increased all-cause mortality, but the prevalence of CHIP in patie

129 art disease death, cardiovascular death, and all-cause mortality by 28% (P=0.020), 25% (P=0.009), and

130 ignancy is associated with increased risk of all cause-mortality, cancer-specific mortality and of de

131 The studied outcomes were all-cause mortality, cardiovascular mortality, and hospi

132 ion is not associated with increased risk of all-cause mortality, cardiovascular mortality, stroke, o

133 ht, systolic blood pressure, and heart rate; all-cause mortality; cardiovascular and cerebrovascular

134 ecipients with PTM were at increased risk of all-cause mortality compared to recipients without PTM (

135 sk prediction models for CKD progression and all-cause mortality compared to similar models with eGFR

136 ed hazard (HR: 1.32; 95% CI: 1.18, 1.48) for all-cause mortality compared with that of subjects who c

137 The model is limited by its reliance on all-cause mortality data, given the lack of reliable cau

138 decreased from 10.0% to 7.6% (P<0.001), and all-cause mortality decreased from 18.0% to 7.9% (P=0.00

139 (RR: 0.93; 95% CI: 0.88, 0.98), the risk of all-cause mortality decreased; higher intake of red meat

140 models, we compared cumulative incidence of all-cause mortality, device-related infection, device re

141 All-cause mortality did not differ significantly between

142 ociated with incident clinical CHD, CVD, and all-cause mortality during 12.5 years of follow-up.

143 In addition, studies had to report on all-cause mortality during a follow-up period of at leas

144 in-1 levels associated with incident CKD and all-cause mortality during follow-up in this general pop

145 All-cause mortality during follow-up.

146 In addition, the all-cause mortality event rates were significantly highe

147 The hazard ratio for all-cause mortality for social isolation compared with n

148 In this population-based cohort study, high all-cause mortality from knee SxOA was mediated mainly t

149 An overall reduction in all-cause mortality, from 28.26% with conventional care

150 We observed a two-fold increase in the all-cause mortality hazard between patients with severe

151 the placebo group in the pooled population (all-cause mortality hazard ratio [HR] 0.52 [95% CI 0.31-

152 Endothelin-1 positively associated with all-cause mortality (hazard ratio for fourth versus firs

153 ular disease risk factors and with increased all-cause mortality (hazard ratio, 2.61; 95% CI, 1.74-3.

154 lasty ring was independently associated with all-cause mortality (hazard ratio: 2.70; 95% confidence

155 All-cause mortality, heart failure hospitalization, and

156 During follow-up, the primary end point of all-cause mortality, heart transplantation, sudden cardi

157 therapy might provide protective benefits on all-cause mortality, hemorrhagic stroke, and new-onset d

158 No associations were found in LURIC with all-cause mortality (highest tertile of lipoprotein(a) c

159 of SGLT2i was associated with lower risk of all-cause mortality, hospitalization for heart failure,

160 was major adverse cardiac events defined as all-cause mortality, hospitalization for myocardial infa

161 mulated in the model, the risk increased for all-cause mortality (HR = 3.39, [95% CI: 2.51-5.42]), al

162 ependently associated with increased risk of all-cause mortality (HR per SD increment: 1.30; 95% CI:

163 R(adj)=0.69, 95% CI 0.56-0.85, p=0.0004) and all-cause mortality (HR(adj)=0.69, 0.58-0.81, p<0.0001)

164 (HR, 0.92; 95% CI, 0.83 to 1.02; P=0.11), or all-cause mortality (HR, 0.96; 95% CI, 0.88 to 1.05; P=0

165 r the combined endpoint of HF readmission or all-cause mortality (HR: 0.90; 95% CI: 0.84 to 0.96; p =

166 CABG, was associated with a similar risk of all-cause mortality (HR: 1.14; 95% CI: 0.99 to 1.32), bu

167 stroke (HR: 2.20; 95% CI: 1.25 to 3.88), and all-cause mortality (HR: 2.26; 95% CI: 1.86 to 2.74), al

168 risk factors, TMAO remained associated with all-cause mortality [HR:1.36 (95% CI, 0.97-1.91),Ptrend

169 -for all-cause mortality, treatment-emergent all-cause mortality, idiopathic-pulmonary-fibrosis-relat

170 end point occurred in 35 patients, including all-cause mortality in 13 patients.

171 measurement after randomization and compared all-cause mortality in 649 patients randomized to placeb

172 The SHFM predicted all-cause mortality in a large cohort with and without I

173 nd day 4 is associated with increased 28-day all-cause mortality in a large sepsis patient population

174 36) was associated with an increased risk of all-cause mortality in a linear dose-response meta-analy

175 potassium values collected at follow-up with all-cause mortality in a prospective and consecutive coh

176 sychosocial covariates, the hazard ratio for all-cause mortality in bereaved siblings versus nonberea

177 form of non-invasive ventilation, decreases all-cause mortality in children with undifferentiated re

178 l other outcomes in all EF categories except all-cause mortality in HFpEF.

179 myocardial infarction (MI), CHD events, and all-cause mortality in Medicare beneficiaries with stati

180 tment SBP levels, cardiovascular events, and all-cause mortality in patients randomized to different

181 affic density were associated with increased all-cause mortality in patients undergoing treatment for

182 these drugs and their combinations regarding all-cause mortality in patients with heart failure with

183 association of primary prevention ICDs with all-cause mortality in patients with nonischemic cardiom

184 eart failure, all-cause hospitalization, and all-cause mortality in patients with prevalent kidney di

185 All-cause mortality in the entire Medicare population fr

186 d by computed tomography are associated with all-cause mortality in the general population.

187 ubsequent risk of cardiovascular disease and all-cause mortality in this population.

188 sity respectively, were associated with late all-cause mortality in U-shaped pattern among long-term

189 I and highest handgrip tertile), the risk of all-cause mortality increased as grip strength reduced w

190 .02-4.08; P=0.037) were each associated with all-cause mortality, independent of traditional CVD risk

191 ls to decompose total effect of knee SxOA on all-cause mortality into indirect and direct effects via

192 bstance abuse conferred the highest risk for all-cause mortality (IRR, 24.8; 95% CI, 21.0-29.4).

193 ted with reduction in 21-day transplant-free all-cause mortality, IRRT (OR, 1.68 [95% CI, 1.04-2.72])

194 , with a nadir for cardiovascular events and all-cause mortality just below the SBP target.

195 ntan failure was defined by the composite of all-cause mortality, listing for heart transplantation,

196 7.4% with both devices with no difference in all-cause mortality (Lotus, 1.9%; ES3, 1.8%; P=0.87), ra

197 ervational studies revealed no difference in all-cause mortality, major adverse cardiovascular events

198 min with those that did not; and 3) reported all-cause mortality, major adverse cardiovascular events

199 bjective of this meta-analysis is to compare all-cause mortality, major adverse cardiovascular events

200 mption had statistically significantly lower all-cause mortality (men: HR, 0.88 [95% CI, 0.82 to 0.95

201 h low dose, high-dose ACEI or ARBs decreased all-cause mortality modestly (relative risk, 0.94; 95% c

202 Evaluated outcomes included all-cause mortality, morbidity and mortality related to

203 factor-R2 were each strongly associated with all-cause mortality, multiple markers of ICU morbidity,

204 SD) also was associated with a lower risk of all-cause mortality [multivariable-adjusted HR: 0.87 (95

205 rombosis (ST), clinically relevant bleeding, all-cause mortality, myocardial infarction, and major ad

206 imary efficacy endpoint was the composite of all-cause mortality, myocardial infarction, ischemia-dri

207 mary efficacy end point was the composite of all-cause mortality, myocardial infarction, ischemia-dri

208 The primary outcome was all-cause mortality; myocardial infarction, revasculariz

209 stroke, cardiovascular disease mortality, or all-cause mortality, nor in total cancer mortality, amon

210 There was no significant difference in all-cause mortality (odds ratio [OR], 0.79; confidence i

211 e events were low, with site-reported 30-day all-cause mortality of 2.2%, cardiovascular mortality of

212 b in ozone were associated with increases in all-cause mortality of 7.3% (95% confidence interval [CI

213 mL/min/1.73 m(2)), TMAO was associated with all-cause mortality only in subjects with eGFR <90 mL/mi

214 Primary end point was all-cause mortality or disabling stroke within 12 months

215 and all-cause mortality and the composite of all-cause mortality or first heart failure hospitalizati

216 None of the secondary end point or day-30 all-cause mortality or heart failure hospitalization rat

217 ates was not associated with improvements in all-cause mortality or heart failure hospitalization.

218 modestly improved the composite end point of all-cause mortality or HF hospitalization without signif

219 post hoc analysis assessed the end point of all-cause mortality or recurrent hospitalization for an

220 The composite primary outcome was defined as all-cause mortality or ventricular arrhythmia, defined a

221 .51; 95% CI: 0.25 to 1.05); and no change in all-cause mortality (OR: 0.91; 95% CI: 0.70 to 1.19).

222 nnually at a treatment facility (volume) and all-cause mortality (outcome).

223 All-cause mortality over 90 days and 1 year after cathet

224 und that ICD use was associated with reduced all-cause mortality (overall hazard ratio: 0.71; 95% con

225 ted that ICD use was associated with reduced all-cause mortality (overall hazard ratio: 0.72; 95% con

226 ICDs), the SHFM was strongly associated with all-cause mortality (p < 0.0001).

227 DF-15 and CRP to be strongly associated with all-cause mortality (P<0.001).

228 h diary users were less likely to experience all-cause mortality (P=0.02 and P=0.01, respectively).

229 compared with placebo for treatment-emergent all-cause mortality (p=0.0420), idiopathic-pulmonary-fib

230 l for aneurysm rupture or repair (P=0.0275), all-cause mortality (P=0.0635), and aneurysm-related mor

231 etter outcomes than nonimprovers (P=0.01 for all-cause mortality; P=0.001 for cardiovascular end poin

232 In conclusion, TMAO is associated with all-cause mortality, particularly in subjects with eGFR

233 Unadjusted rates of AD and all-cause mortality per 1,000 patient-years were higher

234 urrogate covariate in the adjusted model for all-cause mortality: PSA nadir greater than 0.5 ng/mL (a

235 The early initiation group had a 1-year all-cause mortality rate (56 of 111 [50.2%]) significant

236 ed, it remained associated with an increased all-cause mortality rate (9 studies, 3649 patients; RR,

237 (95% CI = 1.1-2.1), and a 2.2-fold increased all-cause mortality rate (95% CI = 1.9-2.5).

238 The primary outcome measure was all-cause mortality rate at 2 weeks after enrolment in p

239 the excess mortality risk, we determined the all-cause mortality rate ratio (MRR) for individuals wit

240 The crude 30-day all-cause mortality rate was 30.8% (97/315).

241 The 1-year all-cause mortality rate was significantly higher in the

242 The 1-year all-cause mortality rate was significantly higher in the

243 We calculated age-standardised all-cause mortality rates (per 100 000 person-years), st

244 veness of the pelvic examination in reducing all-cause mortality, reducing cancer- and disease-specif

245 scularization reduced the primary end point (all-cause mortality, reinfarction, and ischemia-driven r

246 ransfusion was associated with lower risk of all-cause mortality (relative risk [RR] 0.65, 95% CI 0.4

247 0%) and composite of HF hospitalizations and all-cause mortality (relative risk, 0.93; 95% CI, 0.87-1

248 up to two decades after injury, and rates of all-cause mortality remain elevated for many years.

249 ses at diagnosis and factors associated with all-cause mortality, respectively.

250 rrence of the primary composite end point of all-cause mortality, restenosis, or definite stent throm

251 All-cause mortality risk were raised with dental plaque,

252 onoids was associated with decreased risk of all-cause mortality (risk ratio = 0.74, 95% confidence i

253 icantly associated with an increased risk of all-cause mortality (risk ratio [RR] 1.14 [95% CI 1.05-1

254 Brainstem lesions were associated with all-cause mortality (risk ratio, 1.78; 95% CI, 1.01-3.15

255 t patients with and without PPM have similar all-cause mortality (RR, 0.85; 95% CI, 0.70-1.03), cardi

256 s associated with a 2-fold increased risk of all-cause mortality.Selecting specific optimal intakes o

257 ged, uninterrupted bouts are associated with all-cause mortality, suggesting that physical activity g

258 Surgery may have been associated with lower all-cause mortality than observation among men with inte

259 The indirect effect of knee SxOA on all-cause mortality through either a walking disability

260 ulmonary Fibrosis (ASCEND 016; 52 weeks)-for all-cause mortality, treatment-emergent all-cause mortal

261 The primary outcome was all-cause mortality until 28 days.

262 We examined all-cause mortality using adjusted Cox models.

263 ss the associations between R/S and incident all-cause mortality using proportional hazards models.

264 and interval to PSA failure <30 months) for all-cause mortality using the proportion of treatment-ef

265 pooled cohort, the ratio of nominal HRs for all-cause mortality was 0.61 (95% CI, 0.43-0.87) during

266 All-cause mortality was 1.9%, and disabling stroke occur

267 One-year all-cause mortality was 12.4%.

268 All-cause mortality was 27.1% in the hormone therapy gro

269 The incidence of all-cause mortality was 6-fold higher in the pre- interv

270 ing 6 years (median 2.8 years) of follow-up, all-cause mortality was 65% versus 70% for matched patie

271 All-cause mortality was analyzed, evaluating the predict

272 Time to 30-day in-hospital all-cause mortality was evaluated by Kaplan-Meier curves

273 All-cause mortality was higher for nonadherent patients

274 The rate of all-cause mortality was higher for patients not receivin

275 All-cause mortality was higher in candidates with PVD (4

276 All-cause mortality was highest in the year after diagno

277 4 and 18 on death-censored graft survival or all-cause mortality was not confirmed.

278 tween nonfermented milk intake and increased all-cause mortality was recently reported, but overall,

279 The risk of all-cause mortality was significantly greater in partici

280 en SMR was categorized as present or absent, all-cause mortality was significantly higher in the pati

281 R was qualitatively graded, the incidence of all-cause mortality was significantly increased in patie

282 The risk of cardiac and all-cause mortality was similar in both groups.

283 In children younger than 1 year, all-cause mortality was ten (3%) of 374 patients in the

284 All-cause mortality was the primary endpoint.

285 The 28-day all-cause mortality was two-fold higher when procalciton

286 and sugar-sweetened beverages, with risk of all-cause mortality.We conducted a systematic search in

287 s, respectively, and the unadjusted rates of all-cause mortality were 73.0 and 51.6 per 1,000 person-

288 The onset of functional disability and all-cause mortality were followed up for 1,374 d (follow

289 Factors associated with 1-year all-cause mortality were identified using multivariable

290 l infarction, heart failure, and stroke) and all-cause mortality were reported every 6 months and con

291 creasing foods results in a 56% reduction of all-cause mortality, whereas consumption of risk-increas

292 WHR of 0.83 were at the lowest risk of late all-cause mortality, whereas those with BMI beyond the r

293 iations between intake of dairy products and all-cause mortality with an emphasis on nonfermented mil

294 ese trials showed a significant reduction in all-cause mortality with an ICD (hazard ratio, 0.75; 95%

295 These data were adjusted for all-cause mortality with data from the Office for Nation

296 ty) did not demonstrate an overall effect on all-cause mortality with ICD implantation.

297 aborted cardiac arrest), its components, and all-cause mortality with the use of multivariable Cox mo

298 fety outcomes were thromboembolic events and all-cause mortality within 30 days after treatment with

299 The primary outcome measure was all-cause mortality within 30 days of the index laparoto

300 The primary efficacy outcome was all-cause mortality within 30-35 days and the primary sa